In pursuit of a cure, when ideas and options have run out David Fajgenbaum is an assistant professor of medicine at the Perelman School of Medicine at the University of Pennsylvania and associate director of patient impact in the Penn Orphan Disease Center. He also leads the Castleman Disease Research Program.(Image: Courtesy of Penn Medicine) In pursuit of a cure, when ideas and options have run out A new book from Penn Medicine’s David Fajgenbaum chronicles his journey to beat Castleman disease, a rare disorder that he’s lived with for almost a decade.
Could immunotherapy treat diseases besides cancer? Penn In the News Scientific American Could immunotherapy treat diseases besides cancer? Jonathan Epstein of the Perelman School of Medicine is quoted on how immunotherapy has transformed cancer care. Two studies highlight proton therapy for pediatric brain cancer Two studies highlight proton therapy for pediatric brain cancer A pair of new studies done at Penn and the Children’s Hospital of Philadelphia add to the growing body of research showing the potential benefits of proton therapy. A potential new treatment for a deadly form of prostate cancer A potential new treatment for a deadly form of prostate cancer Blocking a specific protein sets off a chain reaction that results in the death of prostate cancer cells that have spread and are resistant to standard therapies. The world’s first T-cell therapy for a solid tumor cancer is made in Philly Penn In the News Philadelphia Inquirer The world’s first T-cell therapy for a solid tumor cancer is made in Philly Carl June of the Perelman School of Medicine commented on news of Iovance Biotherapeutics’ new facilities in South Philadelphia. “Recent advances in the understanding of cancer and the immune system have made a compelling case that [tumor-infiltrating lymphocyte] therapy could be effective in diverse cancers beyond melanoma, such as lung cancer and cervical cancer,” he said. “The decision of Iovance to conduct commercial scale manufacturing in the Philadelphia Navy Yard is wonderful news.” Fertility after cancer Penn In the News U.S. News & World Report Fertility after cancer Christos Coutifaris and Clarisa Gracia of the Perelman School of Medicine spoke about patients’ fertility options after cancer treatment. Experts offer new recommendations for screening more women for breast cancer Penn In the News ABC News Experts offer new recommendations for screening more women for breast cancer Susan Domcheck of the Basser Center for BRCA at the Abramson Cancer Center said that while new recommendations for the screening for BRCA1 and 2 gene mutations are “very valuable,” they don’t address many persistent problems. She stressed the need for additional research regarding BRCA mutations and risk factors, including the effect of race, ethnicity and socioeconomic status. Balance of ‘stop’ and ‘go’ signaling could be key to cancer immunotherapy A molecular model of interferon. Balance of ‘stop’ and ‘go’ signaling could be key to cancer immunotherapy A Penn study shows potential of the interferon pathway as a biomarker to help predict which patients are likely to respond to immunotherapies. A new cancer drug, thanks to a new approach A new cancer drug, thanks to a new approach Researchers in the Abramson Cancer Center helped bring new hope to patients with multiple myeloma with a drug that targets the command center of a cancer cell. Load More
Two studies highlight proton therapy for pediatric brain cancer Two studies highlight proton therapy for pediatric brain cancer A pair of new studies done at Penn and the Children’s Hospital of Philadelphia add to the growing body of research showing the potential benefits of proton therapy.
A potential new treatment for a deadly form of prostate cancer A potential new treatment for a deadly form of prostate cancer Blocking a specific protein sets off a chain reaction that results in the death of prostate cancer cells that have spread and are resistant to standard therapies.
The world’s first T-cell therapy for a solid tumor cancer is made in Philly Penn In the News Philadelphia Inquirer The world’s first T-cell therapy for a solid tumor cancer is made in Philly Carl June of the Perelman School of Medicine commented on news of Iovance Biotherapeutics’ new facilities in South Philadelphia. “Recent advances in the understanding of cancer and the immune system have made a compelling case that [tumor-infiltrating lymphocyte] therapy could be effective in diverse cancers beyond melanoma, such as lung cancer and cervical cancer,” he said. “The decision of Iovance to conduct commercial scale manufacturing in the Philadelphia Navy Yard is wonderful news.” Fertility after cancer Penn In the News U.S. News & World Report Fertility after cancer Christos Coutifaris and Clarisa Gracia of the Perelman School of Medicine spoke about patients’ fertility options after cancer treatment. Experts offer new recommendations for screening more women for breast cancer Penn In the News ABC News Experts offer new recommendations for screening more women for breast cancer Susan Domcheck of the Basser Center for BRCA at the Abramson Cancer Center said that while new recommendations for the screening for BRCA1 and 2 gene mutations are “very valuable,” they don’t address many persistent problems. She stressed the need for additional research regarding BRCA mutations and risk factors, including the effect of race, ethnicity and socioeconomic status. Balance of ‘stop’ and ‘go’ signaling could be key to cancer immunotherapy A molecular model of interferon. Balance of ‘stop’ and ‘go’ signaling could be key to cancer immunotherapy A Penn study shows potential of the interferon pathway as a biomarker to help predict which patients are likely to respond to immunotherapies. A new cancer drug, thanks to a new approach A new cancer drug, thanks to a new approach Researchers in the Abramson Cancer Center helped bring new hope to patients with multiple myeloma with a drug that targets the command center of a cancer cell. Load More
Fertility after cancer Penn In the News U.S. News & World Report Fertility after cancer Christos Coutifaris and Clarisa Gracia of the Perelman School of Medicine spoke about patients’ fertility options after cancer treatment. Experts offer new recommendations for screening more women for breast cancer Penn In the News ABC News Experts offer new recommendations for screening more women for breast cancer Susan Domcheck of the Basser Center for BRCA at the Abramson Cancer Center said that while new recommendations for the screening for BRCA1 and 2 gene mutations are “very valuable,” they don’t address many persistent problems. She stressed the need for additional research regarding BRCA mutations and risk factors, including the effect of race, ethnicity and socioeconomic status. Balance of ‘stop’ and ‘go’ signaling could be key to cancer immunotherapy A molecular model of interferon. Balance of ‘stop’ and ‘go’ signaling could be key to cancer immunotherapy A Penn study shows potential of the interferon pathway as a biomarker to help predict which patients are likely to respond to immunotherapies. A new cancer drug, thanks to a new approach A new cancer drug, thanks to a new approach Researchers in the Abramson Cancer Center helped bring new hope to patients with multiple myeloma with a drug that targets the command center of a cancer cell. Load More
Experts offer new recommendations for screening more women for breast cancer Penn In the News ABC News Experts offer new recommendations for screening more women for breast cancer Susan Domcheck of the Basser Center for BRCA at the Abramson Cancer Center said that while new recommendations for the screening for BRCA1 and 2 gene mutations are “very valuable,” they don’t address many persistent problems. She stressed the need for additional research regarding BRCA mutations and risk factors, including the effect of race, ethnicity and socioeconomic status. Balance of ‘stop’ and ‘go’ signaling could be key to cancer immunotherapy A molecular model of interferon. Balance of ‘stop’ and ‘go’ signaling could be key to cancer immunotherapy A Penn study shows potential of the interferon pathway as a biomarker to help predict which patients are likely to respond to immunotherapies. A new cancer drug, thanks to a new approach A new cancer drug, thanks to a new approach Researchers in the Abramson Cancer Center helped bring new hope to patients with multiple myeloma with a drug that targets the command center of a cancer cell.
Balance of ‘stop’ and ‘go’ signaling could be key to cancer immunotherapy A molecular model of interferon. Balance of ‘stop’ and ‘go’ signaling could be key to cancer immunotherapy A Penn study shows potential of the interferon pathway as a biomarker to help predict which patients are likely to respond to immunotherapies.
A new cancer drug, thanks to a new approach A new cancer drug, thanks to a new approach Researchers in the Abramson Cancer Center helped bring new hope to patients with multiple myeloma with a drug that targets the command center of a cancer cell.